Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37787975.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2260.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent article analyzed paired cell-free DNA among patients with platinum-sensitive BRCA- or PALB2-mutated pancreatic cancer who received maintenance olaparib. Reversion mutations were linked with worse outcomes. These types of paired correlative studies are needed to improve our understanding of drug resistance and guide future clinical trials. See related article by Brown et al., p. 5207.
Medical subject headings
- Antineoplastic Agents
- Ovarian Neoplasms
- Pancreatic Neoplasms